Overcoming Barriers to Effective Treatment and Enrollment in Clinical Trials for Black and Underserved Patients with Multiple Myeloma - Focus Group Panel Discussion
Multiple myeloma (MM) is one of the most common hematologic malignancies in adults and is the most common hematologic malignancy in Black patients. The incidence of MM in the black population is 2-3 times higher than in white patients however, the vast majority of MM clinical trials are conducted on a predominantly white population, resulting in a lack of data regarding MM treatment in Black patients. Our panel of expert Hematology/Oncology faculty convene a patient focus group-informed interactive video discussion emphasizing the treatment and clinical research disparities among Black and underserved patients. The focus groups were comprised of diverse groups of MM patients currently being treated at Boston Medical Center. This educational program builds off the complementary enduring activity to further address existing knowledge gaps related to the racial disparities which impact MM therapy and clinical trial inclusion; highlight ongoing inequities; and provide guidance so that healthcare clinicians can more effectively and equitably treat patients with MM. This activity dives into the results of the focus groups via a moderated panel discussion of the interprofessional care team.
  • Hematology/Oncology
  • Self-study / Enduring
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation